Drug Trial Radar · NCT04881825
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Jun 16, 2021
Primary completion
Apr 30, 2026
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Zealand PharmaIndustry
- Sponsor type
- Industry
- First posted
- May 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is an extension trial to EASE SBS 2. The study looks at whether glepaglutide is a safe treatment for participants with Short Bowel Syndrome (SBS), as well as how well effectiveness is maintained during long term treatment. Participants in this trial will receive glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.) for approximately 2 years.
Conditions
- Short Bowel Syndrome
Interventions
GlepaglutideDrug
Glepaglutide will be delivered in a single-use autoinjector.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and type of Adverse Events (AEs)Time frame: After 108 weeks
Locations
19 sites in 8 countries. Site status is shown where the registry gives one.
Georgetown University Medical Center
Washington D.C., District of Columbia
Mayo Clinic College of Medicin
Rochester, Minnesota
University of Nebraska Medical Center
Omaha, Nebraska
Vanderbilt University Medical Center, Nashville
Nashville, Tennessee
Universitair Ziekenhuis Leuven
Leuven, Belgium
Rigshospitalet
Copenhagen, Denmark
Hôpital Beaujon
Clichy, France
Centre Hospitalier Lyon-Sud
Pierre-Bénite, France
Charité - Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Bonn
Bonn, Germany
Universitätsklinikum Frankfurt
Frankfurt, Germany
Asklepios Kliniken Hamburg GmbH
Hamburg, Germany
Universitätsmedizin Rostock
Rostock, Germany
UMC Radboud Nijmegen
Nijmegen, Netherlands
Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi
Lodz, Poland
Szpital Skawina sp. z o.o. im. Stanley Dudricka
Skawina, Poland
St Mark's Hospital
Harrow, United Kingdom
UCLH Foundation NHS Trust
London, United Kingdom
Norfolk and Norwich University Hospitals
Norwich, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.